Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

In this randomized clinical trial, researchers reported that both topical and systemic finasteride treatments were similarly effective in increasing hair counts and terminal hair in men with androgenic alopecia after more than 3 months of follow-up.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.

This study found that a lipid nanoemulsion-based gel of finasteride for topical use improved hair growth and was effective against alopecia, with slow skin permeation and increased efficacy compared to a testosterone-treated group.

This study explored a novel finasteride-loaded nanoparticle gel for treating alopecia areata, finding that it significantly increased hair follicle number and size without causing skin irritation, presenting an effective alternative to traditional minoxidil treatments.

This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.

In this study, quercetin nanocrystals stabilized with glycyrrhizic acid were developed as a new treatment strategy for androgenetic alopecia, which significantly reduced DHT levels and improved hair regrowth in a mouse model, indicating synergistic potential for clinical application.

This study found that a topical emulsion containing purified extracts of sidr leaves and roasted candlenut seeds significantly increased hair growth compared to the base and 2% minoxidil, potentially through their antioxidant and anti-inflammatory properties.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.

This article reviews the causes, clinical features, and treatment options for androgenetic alopecia, but provides no new clinical findings.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

This review discusses the evaluation and management of male baldness and related conditions, but reports no new clinical results.

This study observed that among dermatologists in Spain, topical minoxidil and oral finasteride are the most commonly prescribed treatments for male androgenic alopecia, while oral dutasteride and oral minoxidil have seen increased use in recent years.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

This report covers an internship at a pharmacy and hospital where multiple pharmaceutical activities were examined, including the preparation of individualized medication and the comparison of drugs for hypercholesterolemia treatment.

Hair loss treated with minoxidil, finasteride, laser/light, hair transplant, and scalp prostheses; more research needed for skin of color.

Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.

This review discusses skin diseases in transgender patients receiving gender-affirming hormone therapy and procedures, highlighting unique conditions and the underdiagnosis that affects their quality of life and mental health.

This review discusses the use of low-dose oral minoxidil for patterned hair loss and reports it may offer improved compliance and safety compared to topical minoxidil, but provides no new clinical findings.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This article reviews treatment options for male androgenetic alopecia, including their distinct aims of arresting progression, stimulating regrowth, and concealing hair loss, and reports no new clinical results.

This review discusses the current role and challenges of compounding in dermatology without presenting new research results; the authors suggest its resurgence in practice despite pharmaceutical alternatives.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review discusses androgenetic alopecia management with 5α-reductase inhibitors, emphasizing that while dutasteride shows superior efficacy, finasteride is suggested as preferable due to predictable adverse effects and preservation of physiological roles.

Hair restoration can be achieved through non-surgical treatments like minoxidil, antiandrogens, phototherapy, and PRP procedures, or through surgical methods like hair transplantation. Continued treatment is needed to maintain results, and full results are visible after 12-18 months.